L-Carnitine, Fat Metabolism, and Liver Health

Carnitine exists as two stereoisomers. L-carnitine is the biologically active form, while D-carnitine is biologically inactive. L-carnitine is synthesized endogenously from the amino acids lysine and methionine and plays a critical role in cellular energy production.

Within the cell, L-carnitine is required for the transport of long-chain fatty acids from the cytosol into the mitochondria, where they undergo β-oxidation to generate metabolic energy. Impaired carnitine availability or function can therefore disrupt fatty-acid oxidation and mitochondrial performance—processes central to metabolic and liver health.

L-Carnitine and Fatty Liver in Diabetes (Animal Data)

Research published in Diabetology & Metabolic Syndrome (2011 Nov 15;3:31) examined the effects of L-carnitine on nonalcoholic fatty liver disease (NAFLD) in streptozotocin-induced type 2 diabetic mice.

Mice were divided into five groups:

  • Healthy controls

  • Untreated diabetic mice

  • Mice pretreated with L-carnitine (125 mg/kg) prior to diabetes induction

  • Diabetic mice treated with L-carnitine (125 mg/kg)

  • Diabetic mice treated with L-carnitine (250 mg/kg)

Supplementation increased hepatic levels of L-carnitine and acetyl-L-carnitine. The authors concluded that L-carnitine improved fatty-acid oxidation and protected mitochondrial function, suggesting a potential role in mitigating fatty liver changes associated with type 2 diabetes. As with all animal research, these findings are mechanistic and hypothesis-generating, not clinical proof.

L-Carnitine as an Adjunct in Hepatitis C Treatment

Human data were explored in a study published in the World Journal of Gastroenterology (2011 Oct 21;17[39]:4414–4420). This study followed 69 patients with chronic hepatitis C undergoing standard therapy with interferon-α plus ribavirin.

Participants were divided into two groups:

  • Drug therapy alone

  • Drug therapy plus L-carnitine supplementation (12 months)

Compared to controls, the L-carnitine group demonstrated:

  • Lower AST (76.8 vs 108.8 U/L)

  • Lower ALT (112.3 vs 137.9 U/L)

  • Improved red blood cell, white blood cell, platelet counts, and hemoglobin levels

The authors concluded that L-carnitine supplementation appeared to support hematopoiesis during antiviral therapy and may help improve treatment tolerance while supporting liver enzyme normalization.